Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Total Assets of $40.56 billion for fiscal year 2025.
REGENERON PHARMACEUTICALS, INC. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $40.56B | +7.4% |
| 2024 | $37.76B | +14.1% |
| 2023 | $33.08B | +13.2% |
| 2022 | $29.21B | +14.9% |
| 2021 | $25.43B | +48.2% |
| 2020 | $17.16B | +15.9% |
| 2019 | $14.81B | +26.2% |
| 2018 | $11.73B | +33.9% |
| 2017 | $8.76B | +25.7% |
| 2016 | $6.97B | +24.3% |
| 2015 | $5.61B | +46.2% |
| 2014 | $3.84B | +30.0% |
| 2013 | $2.95B | +41.8% |
| 2012 | $2.08B | +57.2% |
| 2011 | $1.32B | +21.5% |
| 2010 | $1.09B | +47.0% |
| 2009 | $741.20M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $40.17B | +7.3% | +5.1% |
| June 30, 2025 | $38.22B | +5.9% | +1.8% |
| March 31, 2025 | $37.55B | +9.2% | -0.6% |
| December 31, 2024 | $37.76B | +14.1% | +0.8% |
| September 30, 2024 | $37.44B | +16.4% | +3.8% |
| June 30, 2024 | $36.09B | +17.7% | +5.0% |
| March 31, 2024 | $34.37B | +14.3% | +3.9% |
| December 31, 2023 | $33.08B | +13.2% | +2.9% |
- REGENERON PHARMACEUTICALS, INC. showed an increase of +7.4% in Total Assets compared to the prior fiscal year.
- Over the 2009–2025 period, REGENERON PHARMACEUTICALS, INC.’s total assets has grown by 5372.0% (from $741.20 million to $40.56 billion).
- The most recent figure is from REGENERON PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: